Abstracts

• Introduction

  Douglas E. Joshua

  https://doi.org/10.4081/hmr.v1i11.349

  163

  PDF: 139

  • PDF

• Thalidomide alone or in combination: results in refractory patients

  Jesús F. San Miguel

  https://doi.org/10.4081/hmr.v1i11.350

  245

  PDF: 386

  • PDF

• Retrospective study of thalidomide plus dexamethasone versus conventional chemotherapy in the relapsed multiple myeloma patient and the study of melphalan and prednisone versus melphalan, prednisone, and thalidomide

  Mario Boccadoro

  https://doi.org/10.4081/hmr.v1i11.351

  167

  PDF: 182

  • PDF

• The Intergroupe Francophone du Myélome experience with thalidomide

  Jean-Luc Harousseau, Michel Attal, Thierry Facon, Ibrahim Yakoub-Agha

  https://doi.org/10.4081/hmr.v1i11.352

  211

  PDF: 301

  • PDF

• Thalidomide plus dexamethasone as initial therapy for multiple myeloma: overview of Mayo Clinic and Eastern Cooperative Oncology Group experience

  Robert A. Kyle, Vincent Rajkumar

  https://doi.org/10.4081/hmr.v1i11.353

  158

  PDF: 285

  • PDF

• Panel Discussion

  Dr. Joshua

  https://doi.org/10.4081/hmr.v1i11.354

  147

  PDF: 207

  • PDF